Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506468 | 0.89 | DEGS1 (0.48) | GSK3BDYRK1ABCL2MAPK1DEGS1 | |
| SCHEMBL22606745 | 0.89 | DEGS1 (0.48) | GSK3BDYRK1ABCL2MAPK1DEGS1 | |
| SCHEMBL31726922 | 0.87 | MAPK1 (0.43) | GSK3BDYRK1ABCL2MAPK1DEGS1 | |
| SCHEMBL28071467 | 0.86 | GSK3B (0.41) | GSK3BDYRK1ABCL2MAPK1DEGS1 | |
| SCHEMBL24738966 | 0.86 | GSK3B (0.43) | GSK3BDYRK1ABCL2MAPK1DEGS1 | |
| SCHEMBL27946209 | 0.85 | MAPK1 (0.42) | GSK3BDYRK1ABCL2MAPK1DEGS1 | |
| SCHEMBL16754096 | 0.81 | GRIN2B (0.45) | GSK3BDYRK1ABCL2DEGS1NAMPT | |
| SCHEMBL31727221 | 0.81 | NAMPT (0.41) | GSK3BDYRK1ABCL2MAPK1DEGS1 | |
| SCHEMBL29372377 | 0.80 | RAB9A (0.51) | BCL2MAPK1MAPTRAB9A | |
| SCHEMBL283737 | 0.80 | RAB9A (0.51) | BCL2MAPK1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834527-B2 | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-3027611-B1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-3027611-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-08 | — | — | EP | disclosed |
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| WO-2014198620-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFIA, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-18 | — | — | WO | disclosed |
| CN-100469778-C | Novel fused imidazole derivatives | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | CN | disclosed |
| CN-100348599-C | Novel fused imidazole derivatives | EISAI CO LTD (JP) | 2007-11-14 | — | — | CN | disclosed |
| CN-1931859-A | New fused imidazole derivative | EISAI CO LTD (JP) | 2007-03-21 | — | — | CN | disclosed |
| CN-1675208-A | Novel fused imidazole derivatives | EISAI CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | TFPI, TFPI2, F12 | GSK3B 4040/4885DYRK1A 4136/4885BCL2 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.